$BCT.TO

BriaCell Therapeutics Inks MOU With Dutch Microneedle Company

BriaCell Therapeutics (BCT.TO) has signed a memorandum of understanding (MOU) with a Dutch microneedle company whose device is already being used in its Phase 3 study in advanced metastatic breast cancer.The MOU aims to establish a plan for scaling up of Uneedle's microneedle devices for use in commercial quantities. This is dependent on BriaCell's lead Phase 3 clinical candidate, Bria-IMT, obtaining regulatory approval.Bria-IMT, an immunotherapy candidate, is currently being evaluated in a Phase 3 study in advanced metastatic breast cancer. Uneedle's microneedle technology is being used to intradermally administer Bria-IMT, a statement said.

BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering

BriaCell Therapeutics (BCT.TO, BCTX) was last seen up 5.5% in after-hours Nasdaq trading after the company on Tuesday the closing of its best-efforts share offering that raised $4.7 million.The company placed 1.45-million shares priced at $3.25 each in the offer..The company intends to use proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.BrieCell shares were up US$0.18 at last look to US$3.45, after closing down C$0.05 to C$4.51 on Toronto Stock Exchange.

BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting

BriaCell Therapeutics (BCT.TO) Monday said it is presenting final Phase 2 data from its Bria-IMT trial as well as data from its ongoing Phase 3 trial at the American Society of Clinical Oncology meeting taking place in Chicago.Phase 2 results demonstrated an excellent safety profile and also showed the emergence of a long-term survivor cohort of heavily pretreated metastatic breast cancer patients. Durable survival rates were observed beyond 12 and 24 months, a statement said.BriaCell's Phase 3 data, which addresses a key challenge of limiting toxicity in patients undergoing treatment, is also "encouraging", said Adam Brufsky, professor of medicine at the University of Pittsburgh."We are increasingly optimistic with the early quality of life and biomarker data from our ongoing pivotal Phase 3 Bria-ABC trial demonstrating sustained clinical activity in patients with advanced MBC who did not respond to multiple prior treatments," said William Williams, BriaCell chief executive.BriaCell over the weekend said it plans to raise US$4.7 million in a private placement offering of 1.45 million shares priced at US$3.25 each.BriaCell shares were last seen down $0.46, to $4.57, on the Toronto Stock Exchange.Price: $4.50, Change: $-0.53, Percent Change: -10.54%

BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million

BriaCell Therapeutics (BCT.TO) down 9.3% in U.S. pre-market trading, over the weekend said its offering of 1.45 million shares will be sold at US$3.25 each.Total proceeds of US$4.7 million will be used for working capital requirements.The offering is expected to close on June 2.BriaCell shares were last seen down US$0.32, to US$3.30, in new York trading.

BriaCell Receives DSMB Nod to Continue With Phase 3 Metastatic Breast Cancer Study

BriaCell Therapeutics (BCT.TO), which at last look was down 3.8% in U.S. pre-market trading, has received Data Safety Monitoring Board (DSMB) approval to continue with the Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in patients with metastatic breast cancer, the company said on Tuesday,The recommendation, the sixth, from the board, follows a review of safety data from BriaCell's Phase 3 study, which is being conducted under Fast Track designation granted by the Food and Drug Administration, a statement said.BriaCell shares were last seen down US$0.13, to US$3.36 in New York trading.

BriaCell Says Received Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer

BriaCell Says Presenting Posters, Publication-only Abstracts at ASCO 2026

BriaCell Therapeutics (BCT.TO), down 6% in U.S. pre-market trading, is showcasing three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2 in Chicago, the company said on Friday.The presentations will include two poster presentations featuring data from BriaCell's ongoing Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, Bria-ABC, and one poster highlighting further analyses of Phase 2 data."Our positive clinical data across six presentations or abstracts at the ASCO 2026 Annual Meeting highlight the progress we are making in our clinical programs," said William Williams, BriaCell's chief executive. "These data reflect our commitment to advancing innovative therapeutic options for patients with cancer patients who need better treatments."BriaCell shares were last seen down US$0.22, to US$3.50 in New York trading.

BriaCell Therapeutics Developing Ovarian Cancer Immunotherapy Candidate

BriaCell Therapeutics (BCT.TO), up 1.6% in U.S. pre-market trading, is developing Bria-OVA+, its personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer, the company said on Friday.The company has licensed ovarian cancer cell-lines from American Type Culture Collection (ATCC) and has begun development activities to support production of Bria-OVA+ for potential clinical use."Following the encouraging efficacy and tolerability data from BriaCell's Phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian," said Dr. William Williams, BriaCell chief executive officer."Bria-OVA+ reflects our broader strategy to build on the Bria-OTS+ platform and advance next-generation personalized immunotherapies for difficult-to-treat cancers and become a leader in women's health," he added.BriaCell shares are up US$0.065, to US$4.115 in New York trading.

BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies

BriaCell Therapeutics (BCT.TO), down near 1% in U.S. pre-market trade, has completed manufacturing clinical supplies of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy candidate for prostate cancer, the company said on Thursday.BriaCell was awarded a US$2 million non-dilutive grant from the U.S. National Cancer Institute to support the manufacturing and planned clinical evaluation of Bria-PROS+ last August."The design of Bria-PROS+ is intended to support enhanced immune system activation while maintaining a favorable safety profile. We look forward to advancing Bria-PROS+ into the clinic as we seek to develop new treatment options for prostate cancer patients who do not respond to available therapies," said chief executive William Williams.BriaCell's recent AACR preclinical poster presentation demonstrated Bria-PROS+ activating both adaptive and innate immunity, a statement added. The company believes these preclinical findings support further clinical evaluation as a potential immunotherapy for prostate cancer.BriCell shares were last seen down US$0.04, to US$4.14, on in New York trading.

BriaCell Therapeutics Adds New Clinical Site For Phase 3 Bria-ABC Study

BriaCell Therapeutics (BCT.TO) has added NYU Langone Health's Laura and Isaac Perlmutter Cancer Center, as a clinical trial site in its ongoing Phase 3 clinical study, the company said on Thursday.The Phase 3 clinical study in advanced breast cancer (Bria-ABC) is evaluating the company's lead clinical candidate, Bria-IMT, plus an immune check point inhibitor in advanced metastatic breast cancer.Interim analysis of the Phase 3 study will be conducted after 144 patient events (deaths) have occurred, with overall survival (OS) as the primary endpoint.The Bria-IMT combination regimen has also been granted FDA Fast Track designation.BriaCell shares were last seen up US$0.033, to US$4.183, in U.S. pre-market trading.

BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study

BriaCell Therapeutics (BCT.TO) has received FDA approval to initiate clinical evaluation of its next generation cell-based immunotherapy for metastatic breast cancer, the company said Wednesday.The company, which is developing new immunotherapies, said FDA clearance of its investigational new drug (IND) application opens the way to begin the phase 1/2a clinical study for Bria-BRES+, which features additional immune activating components designed to boost clinical efficacy.Bria-BRES+ builds on Bria-OTS breast cancer clinical program, where the first patient dosed experienced the sustained complete resolution of a lung metastasis. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up, a statement noted."We are honored to announce FDA clearance of the first IND for our next generation personalized immunotherapy, Bria-BRES+," said chief executive William Williams. "The unique design of Bria-BRES+ offers the potential for a favorable safety profile and meaningful therapeutic benefit in metastatic breast cancer. We look forward to advancing Bria-BRES+ into the clinic as we seek to bring new hope to these patients who have few to no effective treatment options."BriaCell shares were last seen down US$0.02, to US$4.05 in New York trading.